Considering the dangers of hemorrhage, especially the fatal consequences of intracranial and gastrointestinal hemorrhage, our study focused on hemorrhagic events potentially associated with anti-HER2 therapy. Here, ERBB2 is linked to Gastrointestinal hemorrhage.